Oleander Medical Technologies
Pre-clinicalDeveloping a revolutionary new treatment to destroy many of the most invasive and deadly cancers using a process called Targeted Osmotic Lysis (TOL).
Founded
1998
Focus
Generic Drugs
About
Developing a revolutionary new treatment to destroy many of the most invasive and deadly cancers using a process called Targeted Osmotic Lysis (TOL).
Company Info
TypePrivate
Founded1998
LocationHouston, United States
StagePre-clinical
Sectors
SIMILAR COMPANIES
BASi Research Products
Pre-clinical · West Lafayette
Bay BioSciences
Pre-clinical · San Francisco
EydisBio
Pre-clinical · Cambridge
3Spine
Pre-clinical · Memphis
Belcher Pharmaceuticals
Pre-clinical · Miami
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile